Related Experiment Video

Updated: Apr 3, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K

Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy

Natalie S Grover1, Steven I Park2

  • 1Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7305, USA.

Pharmaceuticals (Basel, Switzerland)
|September 23, 2015
PubMed

Insights

Novel targeted therapies, including antibody-drug conjugates and immune checkpoint inhibitors, show promise for treating Hodgkin and non-Hodgkin lymphoma, potentially replacing traditional chemotherapy.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Hodgkin and non-Hodgkin lymphoma treatments have advanced with novel targeted agents.
  • These agents include antibodies, antibody-drug conjugates, immune checkpoint inhibitors, and small molecule inhibitors.
  • Emerging therapies show promise in relapsed/refractory and frontline settings.

Purpose of the Study:

  • To review recent advancements in targeted therapies for Hodgkin and non-Hodgkin lymphoma.
  • To discuss approved agents and those in clinical trials.
  • To highlight the potential to reduce or eliminate cytotoxic chemotherapy.

Main Methods:

  • Literature review of recent clinical trials and approved targeted agents.
  • Analysis of novel therapeutic strategies including antibody-based therapies, immune checkpoint blockade, and small molecule inhibitors.
  • Focus on efficacy in relapsed, refractory, and frontline lymphoma treatment settings.

Main Results:

  • Novel targeted agents demonstrate significant promise in Hodgkin and non-Hodgkin lymphoma.
  • Antibodies, antibody-drug conjugates, and immune checkpoint inhibitors are effective in relapsed/refractory disease.
  • Small molecule inhibitors targeting cell signaling pathways also show efficacy.
  • These therapies offer potential to avoid or reduce conventional chemotherapy.

Conclusions:

  • Targeted agents represent a significant advancement in lymphoma treatment.
  • These novel therapies offer new hope for patients with relapsed and refractory disease.
  • The development of targeted therapies may lead to less toxic treatment regimens, potentially avoiding cytotoxic chemotherapy.
Keywords:
Hodgkin lymphomaantibody-drug conjugatesimmune-checkpoint inhibitorsmonoclonal antibodynon-Hodgkin lymphomasmall molecule inhibitors

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

2.0K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
112